Live
- NASA Tracks Five Giant Asteroids on Close Approach to Earth Today
- Pushpa 2 Hits ₹1000 Crore in 6 Days: How It Compares to Other Top Indian Films
- Vivo X200 and X200 Pro Launched in India: Price, Specifications, and Features
- Nitin Gadkari Admits Feeling Embarrassed at Global Summits Over Rising Road Accidents in India
- Comprehensive Review on Indiramma Housing Survey and Welfare Initiatives Conducted via Video Conference
- Jogulamba Temple Records Rs 1.06 Crore Hundi Revenue in 150 Days
- Opposition Slams ‘One Nation, One Election’ Bill as Anti-Democratic; BJP Allies Support the Move
- Celebrate Karthigai Maha Deepam Virtually with Sri Mandir’s LIVE Darshan Experience
- BJP Extends Support to Samagra Shiksha Abhiyan Employees' Strike, Demands Immediate Regularization and Welfare Benefits
- Dr. M. Priyanka Stresses Quality Education, Nutritious Meals, and Cleanliness in Schools
Board of Novartis India to support promoter in strategic review
The board of directors of Novartis India took note of the communication received from Novartis AG, holding company and promoter, regarding their intention to conduct a strategic review to unlock the value of their shareholding in the company.
New Delhi: The board of directors of Novartis India took note of the communication received from Novartis AG, holding company and promoter, regarding their intention to conduct a strategic review to unlock the value of their shareholding in the company.
“After some deliberations, the Board agreed to support Novartis AG, as may be required, in evaluating their strategic options," Novartis India said.
Novartis India Limited is a public company listed on the Bombay Stock Exchange. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company.
Novartis India Limited is separate from Novartis Healthcare Private Limited, the wholly-owned subsidiary of the Novartis group in India.
Novartis Healthcare Private Limited includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Private Limited.
“There can be no assurance that the strategic review of Novartis India Limited will be completed in 2024, or that the outcome would result in the implementation of any transaction," the company said.
“Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years. Today, Novartis proudly employs more than 8,100 associates in India," it said.
